샘플 요청 목록

 카트 문의
시장보고서
상품코드
1514080

당뇨병성 망막증 치료 시장

Diabetic Retinopathy Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 273 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 당뇨병성 망막증 치료 시장은 2030년까지 116억 달러에 이를 전망

2023년에 82억 달러로 평가된 세계의 당뇨병성 망막증 치료 시장은 2023년부터 2030년까지 분석 기간에 CAGR 5.0%로 성장할 전망이며, 2030년에는 116억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 비증식 당뇨병성 망막증은 CAGR 5.6%로 성장을 지속하고, 분석 기간 종료까지 75억 달러에 달할 것으로 예측됩니다. 증식 당뇨병성 망막증 부문의 성장률은 분석 기간 동안 CAGR 4.0%로 추정됩니다.

미국 시장은 22억 달러로 추정, 중국은 CAGR 8.5%로 성장 예측

미국의 당뇨병성 망막증 치료 시장은 2023년 22억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2023년부터 2030년의 분석 기간에서 CAGR 8.5%로 성장을 지속하여 2030년까지 25억 달러 규모에 이를 것으로 예측되고 있습니다. 다른 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.5%와 4.1%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 3.3%로 성장할 것으로 예측됩니다.

당뇨병성 망막증 치료-주요 동향 및 촉진요인

당뇨병성 망막증은 당뇨병 환자가 앓고 있는 심각한 안질환으로 망막의 혈관 손상을 특징으로 하며 방치하면 시력 장애나 실명에 이르기도 합니다. 이 질환은 네 단계를 거쳐 진행되고 망막 혈관에 작은 부종이 생기는 경미한 비증식성 망막증으로 시작하여 혈관 폐색이 진행되는 중등도, 심한 비증식성 단계로 진행하며 마지막으로 증식성 망막증에 이릅니다. 증식기에서는 망막의 표면과 안구의 유리체 겔에서 비정상적인 신생 혈관이 자랍니다. 이러한 신생 혈관은 부서지기 쉽고 혈액이 누출되어 심각한 시력 저하를 유발할 수 있습니다. 당뇨병성 망막증의 치료법은 해마다 크게 진화하고 있으며, 상태를 관리 및 완화하기 위한 다양한 옵션이 제공되고 있습니다. 기존의 치료법에는 누출된 혈관을 막거나 축소시키는 레이저 광응고술과 누출된 혈관에서 유리체 겔과 혈액을 제거하는 수술인 유리체 수술이 있습니다. 그러나, 약리학적 개입, 특히 항-VEGF(혈관 내피 성장 인자) 주사가 최근 점점 더 눈에 띄고 있습니다.

당뇨병성 망막증 치료에서 중요한 동향 중 하나는 약물 요법, 특히 라니비주맙(루센티스), 아프리베르셉트(엘레아), 베바시주맙(아바스틴)과 같은 항-VEGF 약물의 사용이 증가하고 있다는 것입니다. 이러한 주사는 당뇨병 황반부종과 증식 당뇨병성 망막증의 관리의 요점이 되어 레이저 수술을 대체하는 침습이 적은 치료법이 되고 있습니다. 항-VEGF 치료는 망막의 비정상적인 혈관 성장을 가속하는 단백질인 VEGF의 작용을 억제함으로써 효과를 발휘합니다. 임상 및 실제 임상시험은 망막의 부종을 억제하고 시력을 개선하며 추가 질병의 진행을 예방하는 이러한 약물의 효능을 입증합니다. 또 다른 새로운 추세는 주사의 빈도를 줄이고 환자의 컴플라이언스를 향상시키는 것을 목표로 하는 장시간 작용하는 치료제와 서방형 약물 전달 시스템의 개발과 채용입니다. 광간섭 단층계(OCT)와 같은 이미징 기술의 진보는 당뇨병성 망막증의 진단과 모니터링에 혁명을 가져왔습니다. OCT는 망막의 상세한 단면 영상을 제공하여 적시에 효과적인 치료에 필수적인 질병의 조기 발견과 진행의 정확한 평가를 가능하게 합니다. 또한, 당뇨병성 망막증의 검출과 등급화를 지원하는 인공지능(AI) 주도 알고리즘이 개발되어 진단 정밀도와 효율이 더욱 향상되고 있습니다.

당뇨병성 망막증 치료 시장의 성장은 세계 당뇨병 유병률 증가, 당뇨병성 안질환에 대한 의식 증가, 의료 기술의 진보 등 여러 요인에 의해 초래됩니다. 세계 당뇨병의 유행은 인구의 고령화, 앉기 쉬운 라이프 스타일, 건강에 해로운 식생활 등의 요인에 밀려 당뇨병성 망막증의 발병률의 상승으로 이어져 치료 옵션 시장이 확대 하고 있습니다. 또한, 정기적인 안과 검진 및 조기 개입의 중요성에 대해 환자를 교육하는 건강 관리 제공업체 및 조직의 노력이 증가함에 따라 진단 및 치료 솔루션에 대한 수요가 촉진되고 있습니다. 미국 당뇨병 협회(ADA) 및 국제 당뇨병 연합(IDF)과 같은 단체의 공중 보건 캠페인과 이니셔티브는 조기 발견과 관리에 필수적인 당뇨병 안과 검진을 매년 받는 데 중요한 필요성을 강조합니다. 새로운 약리학 약물 개발, 혁신적인 약물 전달 시스템, 진단 도구 개선 등 기술의 진보는 치료 효과와 환자 결과를 향상시키고 있습니다. 게다가 많은 지역에서 정부의 지원 정책과 의료비 증가는 첨단 당뇨병성 망막증 치료에 대한 접근을 촉진하고 있습니다. 또한 망막전문의료센터의 존재감이 높아지고 연구개발에 대한 투자가 증가하고 있는 것도 시장 확대에 기여하고 있습니다.

조사 대상 기업 예(주목 42사)

  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • BCN Peptides SA
  • Genentech, Inc.
  • Glycadia, Inc.
  • Kowa Co., Ltd.
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • Sirnaomics, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global Diabetic Retinopathy Treatment Market to Reach US$11.6 Billion by 2030

The global market for Diabetic Retinopathy Treatment estimated at US$8.2 Billion in the year 2023, is expected to reach US$11.6 Billion by 2030, growing at a CAGR of 5.0% over the analysis period 2023-2030. Non-Proliferative Diabetic Retinopathy, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$7.5 Billion by the end of the analysis period. Growth in the Proliferative Diabetic Retinopathy segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.2 Billion While China is Forecast to Grow at 8.5% CAGR

The Diabetic Retinopathy Treatment market in the U.S. is estimated at US$2.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$2.5 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Diabetic Retinopathy Treatment - Key Trends and Drivers

Diabetic retinopathy is a severe eye condition that affects individuals with diabetes, characterized by damage to the blood vessels in the retina, which can lead to vision impairment and even blindness if left untreated. The condition progresses through four stages, starting with mild non-proliferative retinopathy, where small areas of swelling occur in the retina's blood vessels, advancing to moderate and severe non-proliferative stages, which involve increasing blockage of blood vessels, and culminating in proliferative retinopathy. In the proliferative stage, new, abnormal blood vessels grow on the surface of the retina and into the vitreous gel inside the eye. These new vessels are fragile and can leak blood, causing severe vision loss. The treatment landscape for diabetic retinopathy has evolved significantly over the years, offering various options to manage and mitigate the condition. Traditional treatments include laser photocoagulation, which seals or shrinks leaking blood vessels, and vitrectomy, a surgical procedure to remove the vitreous gel and blood from leaking vessels. However, pharmacologic interventions, particularly anti-VEGF (vascular endothelial growth factor) injections, have become increasingly prominent in recent years.

One of the significant trends in diabetic retinopathy treatment is the increasing use of pharmacologic therapies, particularly anti-VEGF agents like ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin). These injections have become a cornerstone in managing diabetic macular edema and proliferative diabetic retinopathy, providing a less invasive alternative to laser surgery. Anti-VEGF treatments work by inhibiting the action of VEGF, a protein that promotes the growth of abnormal blood vessels in the retina. Clinical trials and real-world studies have demonstrated the efficacy of these agents in reducing retinal swelling, improving vision, and preventing further disease progression. Another emerging trend is the development and adoption of longer-acting treatments and sustained-release drug delivery systems, which aim to reduce the frequency of injections and improve patient compliance. Advances in imaging technologies, such as optical coherence tomography (OCT), have also revolutionized the diagnosis and monitoring of diabetic retinopathy. OCT provides detailed cross-sectional images of the retina, enabling early detection and precise assessment of disease progression, which is crucial for timely and effective treatment. Additionally, artificial intelligence (AI)-driven algorithms are being developed to assist in the detection and grading of diabetic retinopathy, further enhancing diagnostic accuracy and efficiency.

The growth in the diabetic retinopathy treatment market is driven by several factors, including the rising prevalence of diabetes worldwide, increasing awareness about diabetic eye diseases, and advancements in medical technology. The global diabetes epidemic, fueled by factors such as aging populations, sedentary lifestyles, and unhealthy diets, is leading to a higher incidence of diabetic retinopathy, thus expanding the market for treatment options. Additionally, increased efforts by healthcare providers and organizations to educate patients about the importance of regular eye examinations and early intervention are driving demand for diagnostic and therapeutic solutions. Public health campaigns and initiatives by organizations like the American Diabetes Association (ADA) and the International Diabetes Federation (IDF) emphasize the critical need for annual diabetic eye exams, which are essential for early detection and management. Technological advancements, including the development of new pharmacologic agents, innovative drug delivery systems, and improved diagnostic tools, are enhancing treatment efficacy and patient outcomes. Moreover, supportive government policies and increased healthcare expenditure in many regions are facilitating access to advanced diabetic retinopathy treatments. Additionally, the growing presence of specialized retinal care centers and increasing investments in research and development are contributing to the market's expansion.

Select Competitors (Total 42 Featured) -

  • Alimera Sciences, Inc.
  • Allergan PLC
  • Ampio Pharmaceuticals, Inc.
  • BCN Peptides S.A.
  • Genentech, Inc.
  • Glycadia, Inc.
  • Kowa Co., Ltd.
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • Sirnaomics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Diabetic Retinopathy Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Diabetes Generates Demand for Diabetic Retinopathy Treatments
    • Increasing Use of Anti-VEGF Agents Throws the Spotlight on Pharmacologic Therapies
    • Advancements in Imaging Technologies Propel Growth in Early Detection and Monitoring
    • Development of Longer-Acting Treatments Expands Addressable Market Opportunity
    • Integration of AI in Diagnostic Tools Strengthens Business Case for Enhanced Accuracy
    • Technological Innovations in Drug Delivery Systems Propel Market Growth
    • Trends towards Minimally Invasive Treatments Spur Growth in Anti-VEGF Injections
    • Expansion of Specialized Retinal Care Centers Generates Opportunities for Advanced Treatments
    • Impact of Aging Population on Diabetes Prevalence Expands Addressable Market for Treatments
    • Emergence of Personalized Medicine Approaches in Diabetic Retinopathy Treatment Propels Innovation
    • Rising Prevalence of Comorbidities with Diabetes Drives Demand for Comprehensive Care Solutions
    • Growing Use of Telemedicine and Remote Monitoring Tools Expands Market Reach and Adoption
    • Increasing Global Initiatives for Diabetes Management and Retinopathy Prevention Sustain Market Growth
    • Development of Cost-Effective Treatment Options for Emerging Markets Expands Addressable Market Opportunity
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Diabetic Retinopathy Treatment Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Diabetic Retinopathy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Diabetic Retinopathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Non-Proliferative Diabetic Retinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Non-Proliferative Diabetic Retinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Non-Proliferative Diabetic Retinopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Proliferative Diabetic Retinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Proliferative Diabetic Retinopathy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Proliferative Diabetic Retinopathy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Anti-VEGF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Intraocular Steroid Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Intraocular Steroid Injection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Intraocular Steroid Injection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Laser Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Laser Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Laser Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Vitrectomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Vitrectomy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Vitrectomy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital & Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital & Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Hospital & Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Eye Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Eye Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Eye Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: USA 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: USA 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: USA 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Canada 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Canada 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Canada 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • JAPAN
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Japan 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Japan 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Japan 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • CHINA
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: China 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: China 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: China 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • EUROPE
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Diabetic Retinopathy Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Europe 16-Year Perspective for Diabetic Retinopathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Europe 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Europe 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • FRANCE
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: France 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: France 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: France 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • GERMANY
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Germany 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Germany 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Germany 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Italy 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Italy 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Italy 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: UK 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: UK 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UK 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Spain 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Spain 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Spain 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Russia 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Russia 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Russia 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Rest of Europe 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Diabetic Retinopathy Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for Diabetic Retinopathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Asia-Pacific 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Australia 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Australia 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Australia 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • INDIA
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: India 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: India 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: India 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: South Korea 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: South Korea 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: South Korea 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Diabetic Retinopathy Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Latin America 16-Year Perspective for Diabetic Retinopathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Latin America 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Latin America 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Argentina 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Argentina 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Argentina 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Brazil 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Brazil 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Brazil 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Mexico 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Mexico 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Mexico 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Rest of Latin America 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Rest of Latin America 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Rest of Latin America 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Diabetic Retinopathy Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Middle East 16-Year Perspective for Diabetic Retinopathy Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Middle East 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Middle East 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Iran 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Iran 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Iran 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Israel 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Israel 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Israel 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Saudi Arabia 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Saudi Arabia 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Saudi Arabia 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: UAE 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: UAE 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: UAE 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: Rest of Middle East 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: Rest of Middle East 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: Rest of Middle East 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030
  • AFRICA
    • Diabetic Retinopathy Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Diabetic Retinopathy Treatment by Type - Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Africa 16-Year Perspective for Diabetic Retinopathy Treatment by Type - Percentage Breakdown of Value Sales for Non-Proliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy for the Years 2014, 2024 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Diabetic Retinopathy Treatment by Management - Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Africa 16-Year Perspective for Diabetic Retinopathy Treatment by Management - Percentage Breakdown of Value Sales for Anti-VEGF, Intraocular Steroid Injection, Laser Surgery and Vitrectomy for the Years 2014, 2024 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Diabetic Retinopathy Treatment by Distribution Channel - Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Africa 16-Year Perspective for Diabetic Retinopathy Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital & Pharmacies, Ambulatory Surgery Centers, Eye Clinics and Other Distribution Channels for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제